顺铂、培美曲塞、重组人血管内皮抑制素注射液联合治疗晚期肺腺癌的效果评价

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the effects of Cisplatin and Pemetrexed,Recombinant Human Endostatin Injection combined with chemotherapy in the treatment of advanced lung adenocarcinoma.MethodsFrom June 2013 to June 2016,62 patients with advanced lung adenocarcinoma treated in our hospital were selected as objects,and the clinical data was analyzed.30 patients who treated with Cisplatin and Pemetrexed was the control group,32 patients who treated with Cisplatin and Pemetrexed and Recombinant Human Endostatin Injection was the observation group.The treatment effects and adverse reactions were compared between the two groups.ResultsThe disease control rate in the observation group(87.50%)was higher than that in the control group(63.33%),and the difference was statistically significant(P＜0.05).The median tumor progression time in the observation group (8 months)was longer than that in the control group (5.5 months),and the difference was statistically significant(P＜0.05).The life quality increases efficiency were compared between the two groups,and the difference was not statistically significant(P＞0.05).The adverse reaction rate were compared between the two groups,and the difference was not statistically significant(P＞0.05).ConclusionThe treatment of Cisplatin and Pemetrexed and Recombinant Human Endostatin Injection combined application in advanced lung adenocarcinoma,the median time to progression of the tumor was significantly prolonged,and will not increase the adverse reactions of patients.It is an effective treatment,worthy of clinical application.

Key words： Cisplatin Pemetrexed Recombinant human endostatin injection Advanced lung cancer Quality of life

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CONG Yun-yan
	LYU Wei-ze
	LIN Zhong

Cite this article:

CONG Yun-yan,LYU Wei-ze,LIN Zhong. Effect evaluation of Cisplatin,Pemetrexed and Recombinant Human Endostatin Injection in the treatment of advanced lung adenocarcinoma[J]. 中国当代医药, 2017, 24(31): 152-154.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I31/152

[6]	王慧，孙国平.培美曲塞或多西他赛联合顺铂治疗晚期肺腺癌的疗效和不良反应[J].武警医学，2016，27（1）：36－39.
[7]	张朝巍.贝伐单抗与培美曲塞、顺铂联合治疗晚期肺腺癌的临床效果及对VEGF的影响[J].山东医药，2017，57（25）：90－92.
[8]	邹三鹏，薛静.多西他赛联合顺铂与培美曲塞联合顺铂治疗晚期肺腺癌的随机对照研究[J].海南医学，2016，27（8）：1242－1245.
[9]	李长生，任中海.培美曲塞联合顺铂一线治疗晚期肺腺癌疗效及安全性分析[J].中华肿瘤防治杂志，2016，23（18）：1250－1253.
[10]	刘勇，张艳莉，刘岩.培美曲塞联合顺铂治疗晚期非小细胞肺癌疗效观察[J].新乡医学院学报，2015，32（9）：874－876.
[1]	李宏庆，唐中豪，李向阳，等.培美曲塞联合顺铂或卡铂治疗晚期老年肺腺癌的临床对照研究[J].老年医学与保健，2016，22（3）：146－148.
[2]	王晓燕.培美曲塞联合顺铂与埃克替尼治疗晚期肺腺癌的临床疗效比较[J].海峡药学，2017，29（4）：160－162.
[3]	张美霞，徐细明，余婷婷，等.培美曲塞联合顺铂治疗中晚期肺腺癌疗效的Meta分析[J].中国医药，2015，10（3）：335－339.
[4]	侯晓峰，王茹，蔚晓勇.培美曲塞联合顺铂与吉西他滨联合顺铂治疗非小细胞肺癌的疗效比较[J].内蒙古医学杂志，2016，48（6）：674－676.
[5]	潘莹，龚五星，梁翠微，等.晚期非小细胞肺腺癌维持化疗临床研究[J].实用医学杂志，2017，33（7）：1130－1132.
[11]	黄健，黄东宁，覃莉.培美曲塞和顺铂联合同步放疗治疗局部晚期肺腺癌疗效观察[J].医学临床研究，2016，33（3）：467－469.
[12]	廖建斌，郭胜光，万蔚平.培美曲塞联合顺铂治疗老年中晚期非小细胞肺癌的疗效观察[J].中国医院用药评价与分析，2016，16（8）：1040－1042.
[13]	秦亚光，程传耀，王亚秋，等.培美曲塞与多西他赛联合顺铂治疗晚期肺腺癌的临床比较观察[J].肿瘤基础与临床，2016，29（1）：32－35.
[14]	冯丽华，陈毅德，高应勤，等.重组人血管内皮抑制素联合培美曲塞和顺铂方案治疗晚期肺腺癌的临床观察[J].肿瘤研究与临床，2015，27（8）：518－521.
[15]	马汉宸，隋东昕，徐少华.晚期肺腺癌培美曲塞联合顺铂化疗后应用培美曲塞同药维持治疗的临床疗效[J].山东医药，2016，56（33）：99－101.